Center Publications

	Arunagiri, Anoop, et al. “Proinsulin Misfolding Is an Early Event in the Progression to Type 2 Diabetes”. 2019. ELife, vol. 8, 2019.	DOI PubMed PMC	Michigan
	Prahalad, Priya, et al. “Hemoglobin A1c Trajectory in Pediatric Patients With Newly Diagnosed Type 1 Diabetes”. 2019. Diabetes Technology & Therapeutics, vol. 21, no. 8, 2019, pp. 456–461.	DOI PubMed PMC	Stanford
	Herold, Kevan C, et al. “An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes”. 2019. The New England Journal of Medicine, vol. 381, no. 7, 2019, pp. 603–613.	DOI PubMed PMC	Yale
	Chakrabarty, Ankush, et al. “A New Animal Model of Insulin-Glucose Dynamics in the Intraperitoneal Space Enhances Closed-Loop Control Performance”. 2019. Journal of Process Control, vol. 76, 2019, pp. 62–73.	DOI PubMed PMC	Vanderbilt
Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Indiana
			Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Chicago
			Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Washington
			Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Yale
Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Indiana
			Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Chicago
			Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Washington
			Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Yale